Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy (Q34051790)

30 July 2017

title

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy (English)

1 reference

Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography

30 July 2017

1 reference

1 reference

Dong-Young Noh

1 reference

30 July 2017

Yung-Jue Bang

1 reference

30 July 2017

Seock-Ah Im

1 reference

30 July 2017

Do-Youn Oh

1 reference

30 July 2017

Sae-Won Han

1 reference

30 July 2017

Tae-You Kim

1 reference

30 July 2017

Wonshik Han

1 reference

30 July 2017

Woo Kyung Moon

1 reference

30 July 2017

Nariya Cho

1 reference

30 July 2017

June-Key Chung

1 reference

30 July 2017

Bhumsuk Keam

1 reference

30 July 2017

Youngil Koh

1 reference

30 July 2017

Jee Hyun Kim

series ordinal

1 reference

30 July 2017

Keon Wook Kang

series ordinal

1 reference

30 July 2017

In Ae Park

series ordinal

1 reference

30 July 2017

language of work or name

English

0 references

publication date

20 October 2011

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

452

1 reference

Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2--response to therapy, other indications, and future directions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Is there a role for positron emission tomography in breast cancer staging?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

A quantitative review of the use of FDG-PET in the axillary staging of breast cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Locally advanced breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Optimal two-stage designs for phase II clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer.

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-452

Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-452

Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-452

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-452

Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-452

A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-452

Monitoring primary breast cancer throughout chemotherapy using FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-452

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-452

Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3224348

Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy

28 October 2018

1 reference

12 December 2020

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations

1 reference

12 December 2020

Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

12 December 2020

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome

1 reference

12 December 2020

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

12 December 2020

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

1 reference

12 December 2020

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer

1 reference

12 December 2020

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-11-452

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference